AU2004268390B2 - Combinations of a pyrimidine containing NNRTI with RT inhibitors - Google Patents

Combinations of a pyrimidine containing NNRTI with RT inhibitors Download PDF

Info

Publication number
AU2004268390B2
AU2004268390B2 AU2004268390A AU2004268390A AU2004268390B2 AU 2004268390 B2 AU2004268390 B2 AU 2004268390B2 AU 2004268390 A AU2004268390 A AU 2004268390A AU 2004268390 A AU2004268390 A AU 2004268390A AU 2004268390 B2 AU2004268390 B2 AU 2004268390B2
Authority
AU
Australia
Prior art keywords
tmc278
amino
reverse transcriptase
hiv
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2004268390A
Other languages
English (en)
Other versions
AU2004268390A1 (en
Inventor
Paul Stoffels
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Sciences Ireland ULC
Original Assignee
Janssen Sciences Ireland ULC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34280181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2004268390(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Sciences Ireland ULC filed Critical Janssen Sciences Ireland ULC
Publication of AU2004268390A1 publication Critical patent/AU2004268390A1/en
Assigned to TIBOTEC PHARMACEUTICALS LTD. reassignment TIBOTEC PHARMACEUTICALS LTD. Request for Assignment Assignors: TIBOTEC PHARMACEUTICALS LTD.?
Priority to AU2011201123A priority Critical patent/AU2011201123B2/en
Application granted granted Critical
Publication of AU2004268390B2 publication Critical patent/AU2004268390B2/en
Assigned to JANSSEN SCIENCES IRELAND UC reassignment JANSSEN SCIENCES IRELAND UC Request for Assignment Assignors: TIBOTEC PHARMACEUTICALS LTD.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2004268390A 2003-09-03 2004-09-03 Combinations of a pyrimidine containing NNRTI with RT inhibitors Expired AU2004268390B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2011201123A AU2011201123B2 (en) 2003-09-03 2011-03-14 Combinations of a pyrimidine containing NNRTI with RT inhibitors

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US49977103P 2003-09-03 2003-09-03
EP03103275 2003-09-03
EP03103275.8 2003-09-03
US60/499,771 2003-09-03
EP03103319 2003-09-08
EP03103319.4 2003-09-08
EP03103335 2003-09-10
EP03103335.0 2003-09-10
EP03103668 2003-10-02
EP03103668.4 2003-10-02
US50848603P 2003-10-03 2003-10-03
US60/508,486 2003-10-03
PCT/EP2004/052028 WO2005021001A1 (en) 2003-09-03 2004-09-03 Combinations of a pyrimidine containing nnrti with rt inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2011201123A Division AU2011201123B2 (en) 2003-09-03 2011-03-14 Combinations of a pyrimidine containing NNRTI with RT inhibitors

Publications (2)

Publication Number Publication Date
AU2004268390A1 AU2004268390A1 (en) 2005-03-10
AU2004268390B2 true AU2004268390B2 (en) 2011-03-31

Family

ID=34280181

Family Applications (5)

Application Number Title Priority Date Filing Date
AU2004268390A Expired AU2004268390B2 (en) 2003-09-03 2004-09-03 Combinations of a pyrimidine containing NNRTI with RT inhibitors
AU2011201123A Expired AU2011201123B2 (en) 2003-09-03 2011-03-14 Combinations of a pyrimidine containing NNRTI with RT inhibitors
AU2014203484A Active 2027-01-30 AU2014203484B2 (en) 2003-09-03 2014-06-26 Combinations of a pyrimidine containing NNRTI with RT inhibitors
AU2016210733A Active 2027-01-30 AU2016210733B2 (en) 2003-09-03 2016-08-05 Combinations of a pyrimidine containing NNRTI with RT inhibitors
AU2019200813A Abandoned AU2019200813A1 (en) 2003-09-03 2019-02-06 Combinations of a pyrimidine containing NNRTI with RT inhibitors

Family Applications After (4)

Application Number Title Priority Date Filing Date
AU2011201123A Expired AU2011201123B2 (en) 2003-09-03 2011-03-14 Combinations of a pyrimidine containing NNRTI with RT inhibitors
AU2014203484A Active 2027-01-30 AU2014203484B2 (en) 2003-09-03 2014-06-26 Combinations of a pyrimidine containing NNRTI with RT inhibitors
AU2016210733A Active 2027-01-30 AU2016210733B2 (en) 2003-09-03 2016-08-05 Combinations of a pyrimidine containing NNRTI with RT inhibitors
AU2019200813A Abandoned AU2019200813A1 (en) 2003-09-03 2019-02-06 Combinations of a pyrimidine containing NNRTI with RT inhibitors

Country Status (24)

Country Link
US (9) US20080200435A1 (enExample)
EP (1) EP1663240B2 (enExample)
JP (3) JP5507791B2 (enExample)
KR (1) KR20060090658A (enExample)
CN (1) CN101060844B (enExample)
AP (1) AP2109A (enExample)
AU (5) AU2004268390B2 (enExample)
BE (1) BE2015C053I2 (enExample)
CA (1) CA2537095C (enExample)
CY (5) CY2015040I2 (enExample)
FI (1) FI1663240T4 (enExample)
FR (5) FR15C0072I2 (enExample)
HR (1) HRP20150798T4 (enExample)
HU (5) HUS1500054I1 (enExample)
IL (2) IL173438A (enExample)
LT (2) LTPA2016045I1 (enExample)
LU (3) LU92853I2 (enExample)
MX (1) MXPA06002437A (enExample)
MY (1) MY169670A (enExample)
NL (2) NL300781I2 (enExample)
NO (6) NO334877B1 (enExample)
NZ (1) NZ545306A (enExample)
PL (1) PL1663240T5 (enExample)
WO (1) WO2005021001A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US8101629B2 (en) 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
US7399856B2 (en) 2002-08-09 2008-07-15 Janssen Pharmaceutica N.V. Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-2pyrimidinyl]amino]benzonitrile
PT1583542E (pt) 2003-01-14 2008-09-17 Gilead Sciences Inc Composições e métodos para terapia de combinação antiviral
ATE550074T1 (de) * 2004-09-02 2012-04-15 Janssen Pharmaceutica Nv Fumarat aus 4-((4-((4-(2-cyanoethenyl)-2,6- dimethylphenyl amino -2-pyrimidinyl amino benzonitril
SG155885A1 (en) * 2004-09-02 2009-10-29 Janssen Pharmaceutica Nv Furamate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2- pyrimidinyl)amino)benzonitrile
WO2006024667A1 (en) * 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
CA2577288C (en) * 2004-09-02 2010-11-30 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
PT1632232E (pt) * 2004-09-02 2011-08-02 Janssen Pharmaceutica Nv Sal de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]- 2-pirimidinil]amino]benzonitrilo
TWI457136B (zh) * 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) * 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
ATE474560T1 (de) * 2005-12-14 2010-08-15 Cipla Ltd Pharmazeutische kombination aus nucleotid und nucleosid-reverse-transkriptase-hemmern (wie tenofovir und lamivudin) in verschiedenen teilen der dosiereinheit
AR059097A1 (es) * 2006-01-20 2008-03-12 Tibotec Pharm Ltd Tratamiento a largo plazo de la infeccion por vih
US9044509B2 (en) * 2006-02-03 2015-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibition of HIV infection through chemoprophylaxis
FR2903312B1 (fr) 2006-07-05 2008-09-26 Univ Aix Marseille Ii Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
AR065720A1 (es) 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
AU2008353145B2 (en) * 2008-01-03 2013-09-12 Universite D' Aix-Marseille Bitherapy and tritherapy used for treating an HIV-positive patient
MY160360A (en) * 2008-12-24 2017-02-28 Janssen Sciences Ireland Uc Implantable devices for treating hiv
ES2600878T3 (es) 2009-12-21 2017-02-13 Janssen Sciences Ireland Uc Implante removible, degradable, para la liberación prolongada de un compuesto activo
EP3351249A1 (en) 2010-01-27 2018-07-25 VIIV Healthcare Company Antiviral therapy
NZ610729A (en) 2010-11-19 2015-10-30 Gilead Sciences Inc Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
WO2012125993A1 (en) 2011-03-17 2012-09-20 Teva Pharmaceutical Industries Ltd. Solid state forms of rilpivirine base, and rilipivirine salts
EP2755959B1 (en) * 2011-09-16 2018-05-16 Hetero Research Foundation Rilpivirine hydrochloride
EA030003B1 (ru) 2012-12-21 2018-06-29 Джилид Сайэнс, Инк. Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции
CN113546052A (zh) 2015-11-09 2021-10-26 吉利德科学公司 治疗人免疫缺陷病毒的治疗组合物
MA46563B1 (fr) 2016-10-24 2024-01-31 Janssen Sciences Ireland Unlimited Co Compositions dispersibles
US20210128554A1 (en) * 2016-12-23 2021-05-06 Temple University - Of The Commonwealth System Of Higher Education Anti-flaviviridae activity of anti-retroviral non-nucleoside (nnrtis) and nucleoside reverse transcriptase inhibitors (nnrtis)
RU2019136678A (ru) * 2017-04-18 2021-05-18 Сипла Лимитед Комбинированная терапия для применения в лечении ретровирусных инфекций
WO2019021319A1 (en) * 2017-07-27 2019-01-31 Cipla Limited PHARMACEUTICAL COMPOSITIONS
WO2021104487A1 (en) 2019-11-29 2021-06-03 Aptorum Therapeutics Limited Composition including rilpivirine and use thereof for treating tumors or cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996001110A2 (en) * 1994-07-01 1996-01-18 Janssen Pharmaceutica N.V. Anti-hiv triple combination
WO1996041634A2 (en) * 1995-06-13 1996-12-27 Sardinian Antiviral Research Consortium - Sarc S.C.R.L. Use of a non-nucleoside reverse transcriptase inhibitor in association with nucleoside inhibitors for the treatment of hiv infection
WO2003016306A1 (en) * 2001-08-13 2003-02-27 Janssen Pharmaceutica N.V. Hiv inhibiting pyrimidines derivatives

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182111A (en) 1987-11-17 1993-01-26 Boston University Research Foundation In vivo delivery of active factors by co-cultured cell implants
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5368864A (en) 1988-11-25 1994-11-29 Henning Berlin Gmbh Chemie- Und Pharmawerk Formulation of oxypurinol and/or its alkali and alkaline earth salts
MY104575A (en) 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
DK0489181T3 (da) 1990-07-19 1996-11-18 Otsuka Pharma Co Ltd Fast præparat
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
WO1993009176A2 (en) 1991-10-29 1993-05-13 Clover Consolidated, Limited Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release
AU4079593A (en) 1992-05-13 1993-12-13 Wellcome Foundation Limited, The Therapeutic combinations
JPH06316524A (ja) 1992-09-11 1994-11-15 Naoyuki Inoue 抗エイズウイルス剤
US6045829A (en) 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
WO2001021154A2 (en) 1999-09-21 2001-03-29 Rtp Pharma Inc. Surface modified particulate compositions of biologically active substances
US6743446B2 (en) 1999-12-15 2004-06-01 The Ohio State University Research Foundation Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers
TWI284048B (en) 2000-01-27 2007-07-21 Zentaris Ag Compressed microparticles for dry injection
CA2404687A1 (en) 2000-03-30 2001-10-11 Nemichand B. Jain Sustained release beadlets containing stavudine
US20040115268A1 (en) 2000-04-26 2004-06-17 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
DE10050199A1 (de) 2000-10-11 2002-04-25 Ethicon Gmbh Flächiges Implantat mit im Ultraschall detektierbaren Elementen
PL362979A1 (en) 2000-12-11 2004-11-02 Takeda Chemical Industries, Ltd. Medicinal compositions improved in solublity in water
MXPA03011784A (es) 2001-06-22 2004-04-02 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
WO2003043586A2 (en) 2001-11-20 2003-05-30 Advanced Inhalation Research, Inc. Compositions for sustained action product delivery
US7399856B2 (en) 2002-08-09 2008-07-15 Janssen Pharmaceutica N.V. Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-2pyrimidinyl]amino]benzonitrile
WO2004022033A1 (en) 2002-09-04 2004-03-18 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
ATE361059T1 (de) 2002-11-08 2007-05-15 Glaxo Group Ltd Antivirale zusammensetzungen
MXPA05005146A (es) 2002-11-15 2005-07-22 Tibotec Pharm Ltd Indolpiridinio sustituido como compuestos antiinfecciosos.
AU2002350719A1 (en) 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
EP1597237B1 (en) 2003-02-07 2016-07-27 Janssen Pharmaceutica NV Pyrimidine derivatives for the prevention of HIV infection
KR100629771B1 (ko) 2004-01-27 2006-09-28 씨제이 주식회사 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
WO2005123076A2 (en) 2004-06-08 2005-12-29 Vertex Pharmaceuticals, Inc. Pharmaceutical compositions
MY191349A (en) 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
CA2577288C (en) 2004-09-02 2010-11-30 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
PT1632232E (pt) 2004-09-02 2011-08-02 Janssen Pharmaceutica Nv Sal de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]- 2-pirimidinil]amino]benzonitrilo
EP2623095A1 (en) 2004-11-16 2013-08-07 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
TWI457136B (zh) 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
AR056652A1 (es) 2005-04-11 2007-10-17 Tibotec Pharm Ltd Derivados de (1,10-b dihidro-2-(aminoalquil-fenil) -5h-pirazolo (1,5-c) (1,3)benzoxazin-5-il) fenilmetanona y su uso en la fabricacion de un medicamento
CA2603851A1 (en) 2005-04-11 2006-10-19 The Board Of Trustees Of The Leland Stanford Junior Unversity Multi-layer structure having a predetermined layer pattern including an agent
US20090142401A1 (en) 2005-06-07 2009-06-04 Leah Elizabeth Appel Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release
EP1912730A2 (en) 2005-07-28 2008-04-23 Isp Investments Inc. Method to improve characteristics of spray dried powders and granulated materials, and the products thereby produced
AR059097A1 (es) 2006-01-20 2008-03-12 Tibotec Pharm Ltd Tratamiento a largo plazo de la infeccion por vih
PT3366278T (pt) 2006-06-23 2024-10-21 Janssen Sciences Ireland Unlimited Co Suspensões aquosas de tmc278
US20080081064A1 (en) 2006-09-28 2008-04-03 Surmodics, Inc. Implantable Medical Device with Apertures for Delivery of Bioactive Agents
AR065720A1 (es) 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
HRP20131128T1 (hr) 2007-07-12 2013-12-20 Janssen R&D Ireland Kristalni oblik (e) 4-[[4-[[4-(2-cijanoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrila
US20090123508A1 (en) 2007-10-04 2009-05-14 Boston Scientific Scimed, Inc. Implantable Drug Depot for Intrathecal Drug Delivery System for Pain Management
EP2358198A4 (en) 2008-10-24 2012-11-14 Concert Pharmaceuticals Inc HYDROXYETHYLAMINO SULFONAMIDE DERIVATIVES

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996001110A2 (en) * 1994-07-01 1996-01-18 Janssen Pharmaceutica N.V. Anti-hiv triple combination
WO1996041634A2 (en) * 1995-06-13 1996-12-27 Sardinian Antiviral Research Consortium - Sarc S.C.R.L. Use of a non-nucleoside reverse transcriptase inhibitor in association with nucleoside inhibitors for the treatment of hiv infection
WO2003016306A1 (en) * 2001-08-13 2003-02-27 Janssen Pharmaceutica N.V. Hiv inhibiting pyrimidines derivatives

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
British HIV Association (BHIVA) "guidelines for the treatment of HIV-infected adults with antiretroviral therapy" , HIV Medicine 2001 2:276-313 *
Gilead Initiates Study 934, a 48-week Clinical Trial Evaluating Viread? and EmtrivaTM versus Combivir? 11 August 2003. http://web.archive.org/web/20030818001114/http://www.gilead.com/wt/sec/pr_1060631111 ( [8/05/2009 10:17:46 AM] *
Gulick. R. M, "New antiretroviral drugs" Clinical Microbiology and infection 2003 9(3):186-193 *
http://web.archive.org/web/20020822233346/http://thebody.com/confs/aids2002/pavia5.html [8/05/2009 10:13:20 AM]* *
Pavia, A.T. Abacavir/Lamivudine in Combination with Efavirenz, Amprenavir/Ritonavir or Stavudine. 9 July 2002. *
Scaling up Antiretroviral Therapy in Resource-Limited settings 'Guidelines for a public health approach' World Health Organisation, Executive summary April 2002 *

Also Published As

Publication number Publication date
CY2016049I1 (el) 2017-07-12
US20140349971A1 (en) 2014-11-27
CY2015039I2 (el) 2016-08-31
CY2015040I1 (el) 2016-08-31
NO2014030I1 (no) 2015-01-05
AU2014203484B2 (en) 2016-09-29
AU2004268390A1 (en) 2005-03-10
LU92854I2 (fr) 2015-12-21
LU92855I2 (fr) 2015-12-21
EP1663240B1 (en) 2015-04-22
JP2015044839A (ja) 2015-03-12
HUS1500053I1 (hu) 2016-03-29
AU2016210733B2 (en) 2018-11-08
CA2537095C (en) 2012-05-29
AU2011201123A1 (en) 2011-04-07
NL300781I1 (enExample) 2016-04-19
PL1663240T3 (pl) 2015-10-30
US20180228800A1 (en) 2018-08-16
AU2019200813A1 (en) 2019-02-28
MY169670A (en) 2019-05-08
HUS1500054I1 (hu) 2016-03-29
CY2016048I1 (el) 2017-07-12
CN101060844B (zh) 2012-01-04
NL300768I2 (nl) 2023-08-09
AU2016210733A1 (en) 2016-08-25
NO2014032I2 (no) 2014-12-18
FR15C0073I1 (enExample) 2015-04-12
IL173438A (en) 2012-03-29
CY2015038I1 (el) 2016-08-31
NO2014030I2 (no) 2014-12-18
FI1663240T4 (fi) 2023-04-25
FR15C0073I2 (fr) 2016-02-12
AU2011201123B2 (en) 2013-10-10
FR15C0071I1 (enExample) 2015-04-12
NO2014031I1 (no) 2015-01-05
BE2015C053I2 (enExample) 2023-12-14
US20200171027A1 (en) 2020-06-04
LTPA2016045I1 (lt) 2017-01-10
AP2109A (en) 2010-02-26
HRP20150798T4 (hr) 2023-06-09
US20100029591A1 (en) 2010-02-04
US20220008417A1 (en) 2022-01-13
FR15C0072I1 (enExample) 2015-04-12
NZ545306A (en) 2009-11-27
NO2016025I1 (enExample) 2016-12-20
CY2016048I2 (el) 2017-07-12
FR16C1022I1 (fr) 2017-02-03
CY2016049I2 (el) 2017-07-12
AU2014203484A1 (en) 2014-07-17
US20190216807A1 (en) 2019-07-18
HUS1500052I1 (hu) 2016-03-29
NO20061374L (no) 2006-03-27
US8841310B2 (en) 2014-09-23
LTC1663240I2 (lt) 2022-05-25
EP1663240A1 (en) 2006-06-07
NO2016026I1 (no) 2016-12-20
HK1092698A1 (en) 2007-02-16
NL300781I2 (enExample) 2016-04-19
US20080200435A1 (en) 2008-08-21
AP2006003551A0 (en) 2006-04-30
JP5507791B2 (ja) 2014-05-28
JP2012051915A (ja) 2012-03-15
JP2007520443A (ja) 2007-07-26
IL213104A0 (en) 2011-07-31
US20170100398A1 (en) 2017-04-13
NO2014032I1 (no) 2015-01-05
CN101060844A (zh) 2007-10-24
HUS1600059I1 (hu) 2017-02-28
FR15C0072I2 (fr) 2019-05-17
NL300768I1 (enExample) 2015-12-16
WO2005021001A1 (en) 2005-03-10
HUS1600058I1 (hu) 2017-02-28
LU92853I2 (fr) 2015-12-21
LTPA2016044I1 (lt) 2017-01-10
IL173438A0 (en) 2006-06-11
HRP20150798T1 (hr) 2015-09-11
CY2015038I2 (el) 2016-08-31
FR16C1024I1 (fr) 2017-02-03
CY2015039I1 (el) 2016-08-31
CY2015040I2 (el) 2016-08-31
KR20060090658A (ko) 2006-08-14
IL213104A (en) 2016-02-29
US20150283135A1 (en) 2015-10-08
EP1663240B2 (en) 2023-03-01
CA2537095A1 (en) 2005-03-10
NO334877B1 (no) 2014-06-23
JP5820045B2 (ja) 2015-11-24
FR15C0071I2 (fr) 2016-02-12
NO2014031I2 (no) 2014-12-18
MXPA06002437A (es) 2006-06-20
PL1663240T5 (pl) 2024-02-26

Similar Documents

Publication Publication Date Title
AU2011201123B2 (en) Combinations of a pyrimidine containing NNRTI with RT inhibitors
DK1663240T3 (en) COMBINATIONS OF A PYRIMIDINE-CONTAINING NNRTI WITH RT INHIBITORS
HK1092698B (en) Combinations of a pyrimidine containing nnrti with rt inhibitors
HK1165277A (en) Combinations of a pyrimidine containing nnrti with rt inhibitors
ZA200601820B (en) Combinations of a pyrimidine containing NNRTI with RT inhibitors

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTOR NAME FROM STOFFELS, PAUL? TO STOFFELS, PAUL

TC Change of applicant's name (sec. 104)

Owner name: TIBOTEC PHARMACEUTICALS LTD.

Free format text: FORMER NAME: TIBOTEC PHARMACEUTICALS LTD.?

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: JANSSEN SCIENCES IRELAND UC

Free format text: FORMER OWNER WAS: TIBOTEC PHARMACEUTICALS LTD.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired